Cargando…

Enhancing the Therapeutic Effect of 2-(211)At-astato-α-methyl-L-phenylalanine with Probenecid Loading

SIMPLE SUMMARY: To enhance the therapeutic effect of 2-(211)At-astato-α-methyl-L-phenylalanine (2-(211)At-AAMP), a radiopharmaceutical for targeted alpha therapy, we evaluated the effect of probenecid loading on its biodistribution and therapeutic effect in mice. Probenecid preloading significantly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanaoka, Hirofumi, Ohshima, Yasuhiro, Suzuki, Hiroyuki, Sasaki, Ichiro, Watabe, Tadashi, Ooe, Kazuhiro, Watanabe, Shigeki, Ishioka, Noriko S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583516/ https://www.ncbi.nlm.nih.gov/pubmed/34771676 http://dx.doi.org/10.3390/cancers13215514

Ejemplares similares

Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021)

Anti-tumor effects and potential therapeutic response biomarkers in α-emitting meta-(211)At-astato-benzylguanidine therapy for malignant pheochromocytoma explored by RNA-sequencing
por: Ohshima, Yasuhiro, et al.
Publicado: (2019)

Antitumor effects of radionuclide treatment using α-emitting meta-(211)At-astato-benzylguanidine in a PC12 pheochromocytoma model
por: Ohshima, Yasuhiro, et al.
Publicado: (2018)

Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)

3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
por: Vaidyanathan, G., et al.
Publicado: (1997)

Manual on the proper use of meta-[(211)At] astato-benzylguanidine ([(211)At] MABG) injections in clinical trials for targeted alpha therapy (1st edition)
por: Ukon, Naoyuki, et al.
Publicado: (2022)

Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy
por: Sakashita, Tetsuya, et al.
Publicado: (2021)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with (211)At Using Implanted Mouse Tumor
por: Yonekura, Yoshiharu, et al.
Publicado: (2022)

Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of (89)Zr Immune-PET Tracers
por: Imura, Ryota, et al.
Publicado: (2021)

α‐Emitting cancer therapy using (211)At‐AAMT targeting LAT1
por: Kaneda‐Nakashima, Kazuko, et al.
Publicado: (2021)

Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
por: Watabe, Tadashi, et al.
Publicado: (2022)

Targeted α-therapy using astatine ((211)At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound
por: Watabe, Tadashi, et al.
Publicado: (2022)

Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
por: Watabe, Tadashi, et al.
Publicado: (2021)

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
por: Watabe, Tadashi, et al.
Publicado: (2023)

Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine
por: Aso, Ayaka, et al.
Publicado: (2023)

Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
por: Hussaarts, Koen G. A. M., et al.
Publicado: (2020)

Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
por: Kato, Hiroki, et al.
Publicado: (2021)

Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
por: Murray, Jackelyn, et al.
Publicado: (2022)

Astatine-211-Labeled Gold Nanoparticles for Targeted Alpha-Particle Therapy via Intravenous Injection
por: Huang, Xuhao, et al.
Publicado: (2022)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy
por: Gutman, Julie, et al.
Publicado: (2012)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers()
por: Li, Kun-Yan, et al.
Publicado: (2014)

Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers
por: Zhang, Yi-fan, et al.
Publicado: (2016)

A transcriptomic study of probenecid on injured spinal cords in mice
por: Zhang, Yu-Xin, et al.
Publicado: (2020)

Human dosimetry of free (211)At and meta-[(211)At]astatobenzylguanidine ((211)At-MABG) estimated using preclinical biodistribution from normal mice
por: Ukon, Naoyuki, et al.
Publicado: (2020)

Stabilization of an (211)At-Labeled Antibody with Sodium Ascorbate
por: Manabe, Shino, et al.
Publicado: (2021)

Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells
por: Ebert, Regina, et al.
Publicado: (2014)

Oral probenecid improves sperm motility in men with spinal cord injury
por: Ibrahim, Emad, et al.
Publicado: (2018)

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
por: Murray, Jackelyn, et al.
Publicado: (2021)

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
por: Martin, David E., et al.
Publicado: (2023)

Manual on the proper use of sodium astatide ([(211)At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)
por: Watabe, Tadashi, et al.
Publicado: (2021)

Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy
por: Onusko, Evan, et al.
Publicado: (2020)

Inhibitory Effect of Probenecid on Osteoclast Formation via JNK, ROS and COX-2
por: Cheng, Mi Hyun, et al.
Publicado: (2020)

Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
por: Sudo, Hitomi, et al.
Publicado: (2019)

Improved Stability and Practicality for Synthesis of 4-Borono-2-[(18)F]fluoro-l-phenylalanine by Combination of [(18)O]O(2) Single-Use and [(18)F]CH(3)COOF Labeling Agents
por: Naka, Sadahiro, et al.
Publicado: (2022)

Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter
por: Kaneda-Nakashima, Kazuko, et al.
Publicado: (2022)

Properties of $^{211}_{85}$At$_{126}$ as observed in the decay of $^{211}$Rn
por: Astner, G
Publicado: (1972)

Cannot write session to /tmp/vufind_sessions/sess_2ufvunqgsph6h2eln1akh0jreh